Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies

Megan M. Harper; Joseph Kim; Prakash K. Pandalai

doi:10.3390/jcm11102840

Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies

Megan M. Harper, Joseph Kim, Prakash K. Pandalai

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are surgical interventions that directly target peritoneal tumors and have improved outcomes for PC resulting from appendiceal and colorectal cancer (CRC). Despite these radical therapies, long-term survival remains infrequent, and recurrence is common. The reasons for these outcomes are multifactorial and signal the need for the continued development of novel therapeutics, techniques, and approaches to improve outcomes for these patients. Here, we review landmark historical studies that serve as the foundation for current recommendations, recent discoveries, clinical trials, active research, and areas of future interest in CRS/HIPEC to treat PC originating from appendiceal and colorectal malignancies.

Original language	English
Article number	2840
Journal	Journal of Clinical Medicine
Volume	11
Issue number	10
DOIs	https://doi.org/10.3390/jcm11102840
State	Published - May 1 2022

Bibliographical note

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

Funding

Conflicts of Interest: J.K. has received funding from Ipsen for research related to clinical trial NCT04088786. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. All other authors declare no conflict of interest. This research was funded by NIH Training Grant T32CA160003 (M.M.H.).

Funders	Funder number
National Institutes of Health (NIH)	T32CA160003
Ipsen	NCT04088786

Keywords

appendiceal cancer
colorectal cancer
cytoreductive surgery (CRS)
hyperthermic intraperitoneal chemotherapy (HIPEC)
peritoneal carcinomatosis
peritoneal surface malignancies (PSM)

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/jcm11102840

Cite this

@article{6a0de69677d945d9a5eaf706d26f2ff5,

title = "Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies",

abstract = "Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are surgical interventions that directly target peritoneal tumors and have improved outcomes for PC resulting from appendiceal and colorectal cancer (CRC). Despite these radical therapies, long-term survival remains infrequent, and recurrence is common. The reasons for these outcomes are multifactorial and signal the need for the continued development of novel therapeutics, techniques, and approaches to improve outcomes for these patients. Here, we review landmark historical studies that serve as the foundation for current recommendations, recent discoveries, clinical trials, active research, and areas of future interest in CRS/HIPEC to treat PC originating from appendiceal and colorectal malignancies.",

keywords = "appendiceal cancer, colorectal cancer, cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), peritoneal carcinomatosis, peritoneal surface malignancies (PSM)",

author = "Harper, {Megan M.} and Joseph Kim and Pandalai, {Prakash K.}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = may,

day = "1",

doi = "10.3390/jcm11102840",

language = "English",

volume = "11",

number = "10",

}

TY - JOUR

T1 - Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies

AU - Harper, Megan M.

AU - Kim, Joseph

AU - Pandalai, Prakash K.

PY - 2022/5/1

Y1 - 2022/5/1

N2 - Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are surgical interventions that directly target peritoneal tumors and have improved outcomes for PC resulting from appendiceal and colorectal cancer (CRC). Despite these radical therapies, long-term survival remains infrequent, and recurrence is common. The reasons for these outcomes are multifactorial and signal the need for the continued development of novel therapeutics, techniques, and approaches to improve outcomes for these patients. Here, we review landmark historical studies that serve as the foundation for current recommendations, recent discoveries, clinical trials, active research, and areas of future interest in CRS/HIPEC to treat PC originating from appendiceal and colorectal malignancies.

AB - Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are surgical interventions that directly target peritoneal tumors and have improved outcomes for PC resulting from appendiceal and colorectal cancer (CRC). Despite these radical therapies, long-term survival remains infrequent, and recurrence is common. The reasons for these outcomes are multifactorial and signal the need for the continued development of novel therapeutics, techniques, and approaches to improve outcomes for these patients. Here, we review landmark historical studies that serve as the foundation for current recommendations, recent discoveries, clinical trials, active research, and areas of future interest in CRS/HIPEC to treat PC originating from appendiceal and colorectal malignancies.

KW - appendiceal cancer

KW - colorectal cancer

KW - cytoreductive surgery (CRS)

KW - hyperthermic intraperitoneal chemotherapy (HIPEC)

KW - peritoneal carcinomatosis

KW - peritoneal surface malignancies (PSM)

UR - http://www.scopus.com/inward/record.url?scp=85132593973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85132593973&partnerID=8YFLogxK

U2 - 10.3390/jcm11102840

DO - 10.3390/jcm11102840

M3 - Review article

AN - SCOPUS:85132593973

VL - 11

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 10

M1 - 2840

ER -

Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this